Literature DB >> 6600913

Monocyte-induced inhibition of lymphocyte response to phytohaemagglutinin in progressive systemic sclerosis.

M D Lockshin, J A Markenson, L Fuzesi, S Kazanjian-Aram, C Joachim, M Ordene.   

Abstract

In patients with progressive systemic sclerosis (PSS) lymphocyte responses to phytohaemagglutinin (PHA) are abnormal (27.2 +/- 3.5 X 10(-3) counts per minute (cpm) versus 69.8 +/- 4.4 X 10(-3) for normal persons, p less than 0.005). Removal of adherent peripheral blood mononuclear cells improves the response of PSS lymphocytes (42.3 +/- 3.4 X 10(-3) cpm, 155% of control) but diminishes the response of normal lymphocytes (60.3 +/- 5.9 +/- 10(-3), 86% of control). Supernatant fluids from cultures of PSS unfractionated and adherent cells depress normal T cell response to PHA (64% and 55% of control respectively), but supernatant fluids from normal unfractionated and adherent cells do not (104% and 101% of control). Supernatant fluids of PSS and normal adherent cells, cultured in the presence of indomethacin, are not inhibitory to normal T cells (109 +/- 15% and 124 +/- 14% of control respectively). Supernatant fluids from PSS patients are more inhibitory than comparable fluids from patients with systemic lupus erythematosus (60 +/- 8% of control versus 80 +/- 5% of control). These data support the hypothesis that cellular immunity is abnormal in patients with PSS and indicate that adherent mononuclear cells mediate at least one component of the abnormality via an indomethacin-sensitive mechanism.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6600913      PMCID: PMC1001057          DOI: 10.1136/ard.42.1.40

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  25 in total

1.  Circulating T and B lymphocytes in progressive systemic sclerosis.

Authors:  D G de Jesus; R L Clancy
Journal:  J Rheumatol       Date:  1975-09       Impact factor: 4.666

2.  Lymphocyte response to mitogens in progressive systemic sclerosis.

Authors:  N B Salem; J H Morse
Journal:  Arthritis Rheum       Date:  1976 Sep-Oct

3.  The separation of different cell classes from lymphoid organs. IX. A simple and rapid method for removal of damaged cells from lymphoid cell suspensions.

Authors:  H von Boehmer; K Shortman
Journal:  J Immunol Methods       Date:  1973-04       Impact factor: 2.303

4.  Leukocyte migration inhibition in progressive systemic sclerosis.

Authors:  P Hughes; S Holt; N R Rowell
Journal:  Br J Dermatol       Date:  1974-07       Impact factor: 9.302

5.  Cytochemical identification of monocytes and granulocytes.

Authors:  L T Yam; C Y Li; W H Crosby
Journal:  Am J Clin Pathol       Date:  1971-03       Impact factor: 2.493

6.  Lymphocyte reactivity to mitogens in subjects with systemic lupus erythematosus, rheumatoid arthritis and scleroderma.

Authors:  D A Horwitz; M A Garrett
Journal:  Clin Exp Immunol       Date:  1977-01       Impact factor: 4.330

7.  Evidence for cell-mediated immunity to collagen in progressive systemic sclerosis.

Authors:  J M Stuart; A E Postlethwaite; A H Kang
Journal:  J Lab Clin Med       Date:  1976-10

8.  Immunochemical characterization of the anti-RNA antibodies found in scleroderma and systemic lupus erythematosus. I. Differences in reactivity with Poly (U) and Poly-(A) Poly (U).

Authors:  D Alarcón-Segovia; E Fishbein
Journal:  J Immunol       Date:  1975-07       Impact factor: 5.422

9.  Serum antinuclear antibodies in progressive systemic sclerosis (scleroderma).

Authors:  N F Rothfield; G P Rodnan
Journal:  Arthritis Rheum       Date:  1968-10

10.  Uracil-specific anti-R.N.A. antibodies in scleroderma.

Authors:  D Alarcón-Segovia; E Fishbein; E García-Ortigoza; S Estrada-Parra
Journal:  Lancet       Date:  1975-02-15       Impact factor: 79.321

View more
  2 in total

Review 1.  Pathogenesis of scleroderma: the interrelationship of the immune and vascular hypotheses.

Authors:  E M Sternberg
Journal:  Surv Immunol Res       Date:  1985

2.  Increased interferon-gamma (IFN-gamma) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon.

Authors:  M Molteni; S Della Bella; B Mascagni; S Bazzi; C Zulian; S Compasso; M Lessi; R Scorza
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.